YPYunlong Pan

Yunlong Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yunlong Pan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Ding

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, People’s Republic of China

    2 shared publications
  • Fan Pan

    Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), Shenzhen, PR China

    1 shared publication
  • Li Qin

    Department of Histology and Embryology, Medical School of Jinan University, Guangzhou, People’s Republic of China

    1 shared publication
  • Li Qin

    Department of Ophthalmology University of California San Diego La Jolla CA USA

    1 shared publication
  • Shuhao Liu

    Department of Orthopedics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Yanchang Road, Shanghai, 200072, P. R. China

    1 shared publication
  • Wei Li

    Department of Sport Science, Chungnam National University, Daejeon, Korea

    1 shared publication

Latest Publications

  • Open Access

    Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis

    by Yin Leng, Zhixian Chen, Hui Ding, Xiaoxu Zhao, Li Qin, Yunlong Pan

    Background: Recent studies have reported the involvement of microRNA-29 (miR-29) family members in human cancers through their ability to regulate cellular functions. The present study investigated biological function of miR-29b in colorectal cancer (CRC). Methods: CRC tissues and adjacent normal tissues were collected and the expression of ETV4 and miR-29b in the tissues were identified. The relationship between ETV4 and miR-29b or ETV4 expression and the EGFR promoter was identified using dual-luciferase reporter gene and CHIP assays. The proliferation, invasion, migration, and apoptosis of CRC HCT116 cells were assayed using MTT assay, Scratch test, Transwell assay, and flow cytometry, respectively. Also, expression of epithelial-mesenchymal transition (EMT) markers, angiogenic factors, and vasculogenic mimicry formation were evaluated using RT-qPCR and Western blot. Results: ETV4 was upregulated, while miR-29b expression was decreased in CRC tissues. ETV4 was identified as a target gene of miR-29b, which in turn inactivated the ERK signaling pathway by targeting ETV4 and inhibiting EGFR transcription. Transfection with miR-29b mimic, siRNA-ETV4, or ERK signaling pathway inhibitor U0126 increased expression of E-cadherin and TSP-1, and CRC cell apoptosis, yet reduced expression of ERK1/2, MMP-2, MMP-9, Vimentin, and VEGF, as well as inhibiting EMT, angiogenesis, and CRC cell migration and invasion. The EMT, angiogenesis and cancer progression induced by miR-29b inhibitor were reversed by siRNA-mediated ETV4 silencing. Conclusions: miR-29b suppresses angiogenesis and EMT in CRC via the ETV4/ERK/EGFR axis.


  • Open Access

    Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti‑angiogenic treatment

    by Fan Pan, Wei Li, Wende Yang, Xiao‑Yan Yang, Shuhao Liu, Xin Li, Xiaoxu Zhao, Hui Ding, Li Qin, Yunlong Pan

    Anti‑angiogenic therapy provides transient tumor vascular normalization, which results in a window of opportunity for improvement of radio‑ or chemotherapy. Biomarkers indicating this window are required for rationalizing anti‑angiogenesis. Anterior gradient 2 (AGR2), the majority of which is secreted from tumor cells, is an easily detected plasma protein. In the present study, it was demonstrated that AGR2 could be applied as a biomarker for the supervision of vascular normalization during anti‑angiogenic treatment with gold nanoparticles (AuNPs). Nude mice inoculated with SW620 human colorectal cancer cells were treated with AuNPs. Vessel density, pericyte coverage, vessel permeability, tumor hypoxia, tumor growth and AGR2 secretion were detected following treatment with AuNPs at days 0, 4, 6, 9 and 14. Tumor volume and vessel density were reduced, whereas pericyte coverage was increased, and hypoxia and vessel permeability were improved between days 6‑9; however, these improvements decreased by day 14, revealing a time frame for tumor vascular normalization, namely days 4‑9, during treatment with AuNPs in mice. AGR2 levels in tumor tissues and plasma were significantly low at day 9, along with vascular normalization; therefore, AGR2 can be used as a potential marker for monitoring tumor vascular normalization during anti‑angiogenic treatment.